Fig. 3.

Cardiometabolic parameter risk differences with OLZ/SAM compared with olanzapine.^{a a}The odds ratio (95% CI) for developing obesity (BMI ≥30 kg/m²) with use of OLZ/SAM versus olanzapine was 0.52 (0.32, 0.82). Risk differences for shifts in metabolic laboratory parameters were based on sustained potentially clinically significant shifts (ie, the parameters met shift criteria at the last 2 on-treatment assessments). BMI, body mass index; HbA1c, glycosylated hemoglobin; LDL, low-density lipoprotein; OLZ/SAM, combination of olanzapine and samidorphan; WCF, waist circumference.